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ARTICLE
Influence of OATP1B1 Function on the Disposition
of Sorafenib-β-D-Glucuronide
S Bins1, L van Doorn1, MA Phelps2, AA Gibson2, S Hu2, L Li3, A Vasilyeva3, G Du3, P Hamberg4, FALM Eskens1, P de Bruijn1,
A Sparreboom1,2, RHJ Mathijssen1 and SD Baker2,∗
The oral multikinase inhibitor sorafenib undergoes extensive UGT1A9-mediated formation of sorafenib-β-D-glucuronide (SG).
Using transporter-deficient mouse models, it was previously established that SG can be extruded into bile by ABCC2 or follow
a liver-to-blood shuttling loop via ABCC3-mediated efflux into the systemic circulation, and subsequent uptake in neighboring
hepatocytes by OATP1B-type transporters. Here we evaluated the possibility that this unusual process, called hepatocyte hop-
ping, is also operational in humans and can be modulated through pharmacological inhibition. We found that SG transport by
OATP1B1 or murine Oatp1b2 was effectively inhibited by rifampin, and that this agent can significantly increase plasma levels
of SG in wildtype mice, but not in Oatp1b2-deficient animals. In human subjects receiving sorafenib, rifampin acutely increased
the systemic exposure to SG. Our study emphasizes the need to consider hepatic handling of xenobiotic glucuronides in the
design of drug–drug interaction studies of agents that undergo extensive phase II conjugation.
Clin Transl Sci (2017) 00, 1–9; doi:10.1111/cts.12458; published online on yyyy-mm-dd.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔ Sorafenib undergoes extensive UGT1A9-mediated for-
mation of sorafenib-β-D-glucuronide (SG), which is a sub-
strate of the hepatocellular transporter OATP1B1.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔ We hypothesized that sorafenib-β-D-glucuronide can
undergo hepatocyte hopping in humans, and that this pro-
cess can be modulated through pharmacological inhibition.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE?
✔ Our findings signify an unusual contribution of OATP1B1
in the hepatocellular handling of sorafenib in humans,
whereby compromised OATP1B1 function leads to sys-
temic accumulation of sorafenib-β-D-glucuronide.
HOW THIS MIGHT CHANGE CLINICAL PHARMACOL-
OGY OR TRANSLATIONAL SCIENCE
✔ Our study emphasizes the need to consider hepatic han-
dling of xenobiotic glucuronides in the design of drug–drug
interaction studies of agents that undergo extensive phase
II conjugation.
The multikinase inhibitor sorafenib is used as a chemother-
apeutic agent in the treatment ofmultiplemalignant diseases,
including cancers of the liver, kidney, and thyroid.1–3 The
pharmacokinetic properties of orally administered sorafenib
are characterized by up to 90% variation in exposure
between patients receiving the same therapeutic regimen.4
The high degree of interindividual pharmacokinetic variabil-
ity observed with sorafenib has important toxicological ram-
ifications. For example, it was recently demonstrated that
levels of sorafenib in plasma are correlated with the inci-
dence of skin rash,5 with dose reduction and study with-
drawal due to adverse effects,6 and with the development
of severe adverse reactions.7
The mechanisms underlying the unpredictable pharma-
cokinetic profile of sorafenib remain largely unexplained.
After oral administration, sorafenib enters hepatocytes by
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incompletely defined mechanisms,8,9 and then undergoes
CYP3A4-mediated oxidation10,11 and UGT1A9-mediated
glucuronidation.11 A mass balance study of oral sorafenib
in humans has shown that 15% of the dose was elim-
inated as sorafenib-β-D-glucuronide (SG), compared with
less than 5% as oxidative metabolites. Interestingly, SG was
not detectable in feces, which may be due to its instability
in the presence of bacterial glucuronidases present in the
gut.12 Therefore, it has been suggested that the actual contri-
bution of glucuronidation to sorafenib elimination may have
been underestimated in the mass balance study,9 and that,
because of its effective secretion into bile,13 the appearance
of SG in the systemic circulation represents an overshoot
mechanism that poorly reflects the actual extent of its for-
mation. These observations suggest that a critical determi-
nant of sorafenib’s pharmacokinetic variability with possible
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Figure 1 Hepatocyte hopping and recirculation of sorafenib-β-D-glucuronide. After oral administration, sorafenib enters the hepatocytes
by incompletely defined transporters mechanisms, including OATP1B-type carriers and OCT1, and undergoes ABCG2-mediated biliary
secretion, CYP3A4-mediated metabolism to sorafenib-N-oxide (S-N-oxide), or UGT1A9-mediated glucuronidation to form sorafenib-β-
D-glucuronide (SG). After conjugation, SG is extensively secreted into the bile by a process that is mainly mediated by ABCC2. Under
physiological conditions, a fraction of the intracellular SG is secreted by ABCC3 and at least one other transporter back to the blood, from
where it can be taken up again into downstream hepatocytes via OATP1B-type carriers. This secretion-and-reuptake loop may prevent the
saturation of ABCC2-mediated biliary excretion in the upstream hepatocytes, thereby ensuring efficient biliary elimination and hepatocyte
detoxification. Once secreted into bile, SG enters the intestinal lumen, where it can either be excreted or serve as a substrate for an
as-yet unknown bacterial β-glucuronidase that produces sorafenib, which is subsequently undergoing intestinal absorption and reenters
the systemic circulation. This figure is a modified version of a figure from Vasilyeva et al.13 and is reprinted with permission.
consequences for clinical management may be associated
with differential expression and function of SG transporters
regulating its distribution and elimination.14
After its formation, SG is secreted into the bile through
a process mediated by the adenosine triphosphate (ATP)-
binding cassette efflux transporter ABCC2 (MRP2).13 Under
normal physiologic conditions, a fraction of the hepatocel-
lular SG is secreted back into the bloodstream by ABCC3
(MRP3), fromwhere it can be taken up again into downstream
hepatocytes via the uptake carrier OATP1B1 (Oatp1b2 in
mice) (Figure 1).13 This liver-to-blood shuttling loop, called
hepatocyte-hopping, may prevent saturation of ABCC2-
mediated biliary secretion of endogenous and xenobiotic glu-
curonides in upstream hepatocytes, thereby ensuring their
efficient biliary elimination and hepatocyte detoxification.
Once secreted into bile, SG enters the intestinal lumen, where
it serves as a substrate for a bacterial β-glucuronidase that
produces sorafenib, which subsequently undergoes intesti-
nal absorption and then reenters the systemic circulation.13 In
the current proof-of-concept study, we tested the hypothesis
that the hepatocyte hopping of SG can be interrupted by a
clinical OATP1B1-mediated drug–drug interaction based on
the expectation that inhibition of a hepatic uptake mecha-
nism will lead to acute increases in levels of SG in plasma.
MATERIALS AND METHODS
Cell lines and chemicals
A model of OATP1B1-expressing cells was created by
transfecting HEK293 cells with the pIRES2-EGFP vector
(Clontech, Mountain View, CA) containing SLCO1B1
cDNA. Similarly, HEK293 cells were transfected with the
pDream2.1/MCS vector (GenScript, Piscataway, NJ) con-
tainingSlco1b2 cDNA. TheHEK293 (ATCCCRL1573) cell line
was obtained from American Type Culture Collection (ATCC,
Manassas, VA). This cell line was exclusively used to study
drug transport, and was not authenticated by the authors. All
stable cell lines were selected and maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (FBS) and G418 sulfate (500–1,000
μg/mL; AG Scientific, San Diego, CA) at 37°C under 5%CO2.
Sorafenib and rifampin were obtained from Chemie Tek
(Indianapolis, IN). General tritium-labeled sorafenib (specific
activity, >1 Ci/mmol; radiochemical purity, >97.1%) was
custom made by Moravek Biochemicals (Brea, CA), and
[3H]estradiol-17β-D-glucuronide (E2G; specific activity, 50.1
Ci/mmol; radiochemical purity, 99.0%), a positive control
substrate for OATP1B1 and Oatp1b2, was obtained from
American Radiolabeled Chemicals (St. Louis, MO).
Uptake studies
Cells were seeded in 6-well plates in phenol red-free DMEM
media containing 10% FBS, and were incubated at 37°C for
24 h. Cells were then washed with warm phosphate-buffered
saline (PBS) and incubated with sorafenib or SG in phenol-
free DMEM media (without FBS and supplements) at 37°C.
Uptake and inhibition studies were performed as outlined
in detail elsewhere.13 The experiment was terminated by
placing cells on ice and washing twice with ice-cold PBS.
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Cells were collected and centrifuged at 1,050 r.p.m. for 5
min at 4°C. The cell pellet was lysed in 1 N NaOH by vortex-
mixing, incubated at 4°C overnight, and then the solution
was neutralized with 2 M HCl. Total protein was measured
using a Pierce BCA Protein Assay Kit (ThermoScientific,
Waltham, MA) and total protein content was quantified using
a Biotek μQuant microplate spectrophotometer (Winooski,
VT). Intracellular E2G concentrations were determined in the
remaining cell lysate by liquid scintillation counting using
a LS 6500 Multipurpose Scintillation Counter (Beckman,
Brea, CA). The experiments were performed in triplicate.
Intracellular concentrations of SG were measured by liquid
chromatography-tandem mass spectrometry (LC-MS/MS),
as described previously.11
Transcellular transport
MDCKII cells were transduced with pIRES2 construct
containing CFP-ABCC2-V5, GFP-OAT1B1-FLAG, or GFP-
OATP1B1-FLAG/CFP-ABCC2-V5 (Supplementary Figure
S1). TheMDCKII (ATCCCRL2936) cell line was obtained from
ATCC. This cell line was exclusively used to study drug trans-
port, and was not authenticated by the authors. Transport of
SG (1 μM) was performed in 6-well plates (Corning, Corning,
NY), as described,11 Trans-epithelial electrical resistancewas
measured to confirm the integrity of cell monolayers.
Immunofluorescence
MDCKII cells transduced with CFP-ABCC2-V5 and/or GFP-
SLCO1B1-FLAG were seeded at 2 × 105 cells/well into
6-transwell plates. When they reached about 90% conflu-
ence, cells were washed with ice-cold PBS, fixed with 4%
paraformaldehyde-PBS, permeabilized with 0.1% TritonX-
100-PBS, and incubated in 3% BSA-PBS blocking buffer.
Then cells were stained with either anti-V5 (Sigma-Aldrich,
St. Louis, MO) or anti-FLAG M2 (Sigma-Aldrich) followed
by staining with Alexa488 and Alexa568 (Life Technolo-
gies, Camarillo, CA), respectively, along with DAPI (Invitro-
gen, La Jolla, CA) to stain the nuclei. Transwell membranes
were cut out and placed on a slide, covered with a cover-
slip, and sealed. Imaging was done using a Marianas spin-
ning disk confocal (SDC) imaging system (Intelligent Imaging
Innovations/3i) based on AxioObserver Z1 inverted micro-
scope (Carl Zeiss MicroImaging, Peabody, MA). Images were
acquired with a Zeiss Plan-Apochromat 63 × 1.4 NA DIC
objective and Evolve 512 EMCCD camera (Photometrics,
Tucson, AZ) using SlideBook 5 software (3i).
Murine pharmacokinetics
Female mice knockout for Oatp1b2 [Oatp1b2(-/-)] and age-
matched wildtype mice on a DBA1/lacJ background were
bred in-house.Micewere housed in a temperature-controlled
environment with a 12-h light cycle and given a standard
diet and water ad libitum. Experiments were approved by the
Institutional Animal Care and Use Committee.
Sorafenib was formulated in 50% Cremophor EL (Sigma-
Aldrich) and 50%ethanol, and diluted 1:4 (vol/vol) with deion-
ized water immediately before administration by oral gavage
at a dose of 10 mg/kg. Mice were fasted for 3 h before and
during the study, with unrestricted access to drinking water.
In Oatp1b2(-/-) and wildtype mice (N= 4 per group), rifampin
(20 mg/kg) was administered intravenously 5 min prior to
the oral sorafenib administration. At select timepoints, blood
samples (30 μL each) were taken from individual mice at
0.25, 0.5, and 1.5 h from the submandibular vein using a
lancet, and at 3, and 4.5 h from the retro-orbital venous
plexus using a capillary. A final blood draw was obtained at
7.5 h by a cardiac puncture using a syringe and needle. For
sampling via retro-orbital bleeding, mice were anesthetized
under 1–5% isoflurane through inhalation, and blood was
collected using a heparinized capillary tube. The total blood
volume collected during the procedure from eachmouse was
150 μL. All blood samples were centrifuged at 3,000 ×
g for 5 min, and plasma was separated and stored at –
80°C until analysis. At the terminal timepoints, liver samples
were immediately collected and flash-frozen on dry ice. Liver
specimens were stored at –80°C until further processing.
Plasma and liver concentrations of sorafenib, sorafenib-N-
oxide, and SG were determined by LC-MS/MS, as described
previously.11 Pharmacokinetic parameters were calculated
using WinNonlin 6.3 software (Pharsight, Princeton, NJ).
Clinical studies
Patients were enrolled and received standard of care treat-
ment with sorafenib in an open-label randomized crossover
trial. The principle inclusion criteria were: age 18 years,
confirmed diagnosis of cancer, WHO performance score
0–1, and adequate organ function, which was defined as
absolute neutrophil count >1.0 × 109/L and platelet count
60 × 109/L for bone marrow function; as serum creatinine
<1.25×ULN (upper limit of normal) for renal function; and as
total bilirubin <1.25 × ULN, aminotransferases <5 × ULN,
prothrombin time 1.5 × ULN or international normalized
ratio <1.5 for hepatic function. Also, patients were required
to have reached steady state, which was defined as at least
14 days of treatment with the same sorafenib dose. The
major exclusion criteria were: prior liver transplantation,
contraindications for any of the study drugs, and use of
any comedication or supplement that is known to cause
interactions with the study drugs. The mean steady-state
(trough) concentration (Css) of SG used in the sample size
calculation was 954 ng/mL, estimated from a group of 16
cancer patients receiving sorafenib at an oral dose of 90
mg/m2 that had sampling for pharmacokinetics on three
consecutive occasions, namely, on days 7, 13, and 21.15
In this group of patients, the standard deviation (SD) of the
expected differences of the two measurements (sorafenib
given without and with rifampin) was estimated to be 223
ng/mL. It was assumed that the interval between treatments
represents an adequate washout period, with no carryover
or period effect. The clinical study was designed to detect
an effect size of 239/223, where 239 is 25% of the mean Css
of SG. Based on a pairwise (two-sided) analysis, this results
in a sample size of nine for the prospective evaluation, with a
significance level of 0.05 and power of 0.8. All other pharma-
cokinetic end points were assessed exploratorily. Between
August 2013 and March 2015, nine evaluable patients with
hepatocellular carcinoma were included in the clinical study,
of whom eight were male and one was female. The mean
age was 71 years (range, 62–79) and all patients had a
WHO performance score of 1. Patients were randomized by
www.cts-journal.com
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minimization using the web-based application Trial Online
Process (TOP). Patient characteristics were entered in TOP
by one of the investigators and the patient’s trial number and
randomization arm were then sent to all investigators in an
automatic email from TOP. Four patients were randomized
to receive rifampin during the first sampling period (arm
A), and five were randomized to rifampin during the sec-
ond period (arm B). The administered sorafenib (Nexavar;
Bayer, The Netherlands) dose was 200 mg b.i.d. for four
patients (three in arm A, one in arm B) and 400 mg b.i.d.
for five patients (one in arm A, four in arm B). The study
was approved by the Institutional Review Board (Protocol
number, MEC 2013–194), and registered in the Dutch Trial
Registry (www.trialregister.nl; number NTR4110). All patients
provided written informed consent, and the study was
conducted in accordance with Good Clinical Practice guide-
lines and the Declaration of Helsinki (59th WMA General
Assembly, Seoul, Republic of Korea; October 2008).
Subjects were admitted to the hospital for 2 separate
days of blood sampling: once with prior rifampin adminis-
tration and once without. Days of blood sampling were sep-
arated by a period of 9 days. Rifampin was taken without
food as 600 mg tablets (Rifadin; Sanofi-Aventis, The Nether-
lands) on the day before and on the day of sampling at 8
AM, exactly 1 h before sorafenib administration. Two and
a half h after sorafenib intake, midazolam (2.5 mg; Actavis,
The Netherlands) was administered intravenously as a probe
for CYP3A4 activity.16 During both hospitalizations, blood
samples (6 mL each) for the determination of sorafenib and
metabolite levels were collected just before the administra-
tion of sorafenib, and 2, 4, and 7.5 h after the administra-
tion of sorafenib. Samples were prepared by centrifugation
at 1,200 × g for 5 min to obtain plasma, which was stored
at –80°C until analysis. Plasma concentrations of sorafenib,
sorafenib-N-oxide, and SG were determined by LC-MS/MS,
as described and validated previously.11,15,17 Concentrations
of midazolam and its metabolites were measured in three
plasma samples taken 2, 4, and 6 h after midazolam adminis-
tration during both sample periods. The midazolam samples
were centrifuged and stored as described above. WinNon-
lin 6.3 (Pharsight) was used for calculating pharmacokinetic
parameters.
Patients were seen in the outpatient clinic on a weekly
basis for clinical examination, laboratory tests, and to eval-
uate possible side effects. Skin toxicity and diarrhea were
managed according to local institutional guidelines. Adverse
events were registered according to the National Cancer
Institute’s Common Terminology Criteria for Adverse Events
(CTCAE), v. 4.03. During the study, dose changes of sorafenib
and the use of comedication that is known to influence
CYP3A4 function were not allowed.
Statistical analysis
Pharmacokinetic data are presented as geometric mean and
95% confidence interval. In patients receiving sorafenib at
a dose of 200 mg b.i.d., dose-dependent pharmacokinetic
parameters such as the area under the curve (AUC) and
absolute observed concentrations were normalized to a dose
of 400 mg b.i.d.; that is, parameters were multiplied by a fac-
tor of 2. This procedure is justified as sorafenib is known
to exhibit a linear pharmacokinetic profile within this dose
range.18 Statistical analysis was performed using GraphPad
Prism 5.0 (GraphPad Software, La Jolla, CA). Uptake rates
in the in vitro experiments were compared using unpaired t-
tests. Geometric means of the pharmacokinetic parameters
in mice were compared using analysis of variance (ANOVA),
whereas those in humans were compared using two-
sided paired t-tests. P < 0.05 was considered statistically
significant.
RESULTS
Influence of rifampin on SG transport in vitro
Experiments were initially carried out with HEK293 cells
engineered to express OATP1B1 or its murine equivalent
Oatp1b2 using the recommended model substrate estradiol-
17β-glucuronide (E2G),19 and the clinically relevant OATP1B-
type transporter inhibitor rifampin.20 Following a 15-min incu-
bation period, E2G uptake by human OATP1B1 and mouse
Oatp1b2 was strongly inhibited by a preincubation with
rifampin (30 μM) (P = 0.001 and P < 0.001, respectively;
Figure 2a,b). Since rifampin-mediated inhibition of OATP1B1
can be substrate-dependent, with up to 12-fold variation in
IC50 values,21 we next used SG as a test substrate in the
same models. Similar to E2G, rifampin reduced the intracel-
lular uptake of SG by both OATP1B1 and Oatp1b2 by 92%
(P = 0.004) and 97% (P > 0.001), respectively (Figure 2a,b).
This process was dependent on the rifampin concentration
(Figure 2c). The resulting IC50 values of 1 μM for both
OATP1B1 and Oatp1b2 were similar to those reported previ-
ously for uptake inhibition by rifampin of other substrates.22
As plasma Cmax of unbound rifampin is1.3μM (1.1 mg/L),23
the intrinsic likelihood of an OATP1B1-mediated pharma-
cokinetic drug–drug interaction between rifampin and SG is
high.
Because rifampin is also a known inhibitor of various
ABC transporters,24 and can influence the transport of SG
in inside-out vesicles expressing ABCC2,13 we next evalu-
ated the influence of rifampin on the flux of SG in MDCKII
cells engineered to overexpress OATP1B1, ABCC2, or both
OATP1B1 and ABCC2 (Supplementary Figure S1). Trans-
fection of OATP1B1 (basolaterally localized) into MDCKII
cells significantly increased the basal-to-apical transport of
SG, and this translocation was diminished in the presence of
rifampin (Figure 2d). However, the basal-to-apical flux of SG
was not substantially enhanced by co-transfection of ABCC2
(apically localized), and not further reduced by rifampin in
cells expressing both OATP1B1 and ABCC2 (Figure 2d).
This suggests that rifampin can be utilized for in vivo stud-
ies as a bona fide inhibitor of SG transport by OATP1B-type
carriers.
Effects of rifampin on SG disposition in mice
The in vivo role of rifampin (20 mg/kg) in the transport of SG
was next evaluated in wildtype mice and Oatp1b2-deficient
[Oatp1b2(-/-)] littermates receiving a single oral dose of
sorafenib (10 mg/kg). This experiment was based on the
expectation that the systemic exposure to SGwould increase
by rifampin in an Oatp1b2-dependent manner, as predicted
from our in vitro transport experiments. In line with our
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Figure 2 Transport of SG by OATP1B-type transporters. Transport of estradiol-17β-glucuronide (E2G; 0.1 μM) and sorafenib-β-D-
glucuronide (SG; 10 μM) in HEK293 cells engineered to overexpress OATP1B1 (a) or Oatp1b2 (b) with or without rifampin (20 μM). All
results are normalized to the transport rate in OATP1B transfected cells without rifampin, i.e., the experiments with unrestricted OATP1B
effect, which were 4.77 pmol/mg protein (OATP1B1) and 26.73 pmol/mg protein (Oatp1b2) in 15 min for E2G, and 57.46 pmol/mg protein
(OATP1B1) and 770.17 pmol/mg protein (Oatp1b2) in 15 min for SG. (c) Inhibition of OATP1B1 or Oatp1b2-mediated transport of SG (10
μM) by different concentrations of rifampin (0–100 μM). Data are normalized to the relative uptake without rifampin, i.e., when the function
of OATP1B is unrestricted, and represent the mean ± SE from 3–4 independent experiments (9–12 replicates). (d) Transcellular transport
of SG in MDCKII cells expressing OATP1B1 and/or ABCC2. Cells were incubated with SG (1 μM), and 50-μl aliquots were taken at 1,
2, 3, and 4 h from the compartment opposite to where the drug was added, in the presence or absence of rifampin (100 μM). Data are
expressed as transporter-mediated apparent permeability coefficient (Papp) for the basolateral to apical direction (B-to-A). Data represent
the mean ± SE (at least three replicates).
previous findings,9 Oatp1b2-deficiency in mice was associ-
ated with a significant 8-fold increase in SG AUC0-7.5h (Figure
3; Supplementary Table S1).
The liver-to-plasma ratio of SG was reduced by 90%
in wildtype mice pretreated with rifampin, and similar to
that observed in Oatp1b2(-/-) mice receiving sorafenib either
alone or when given in combination with rifampin (Figure
3c). Oatp1b2-deficiency and/or rifampin pretreatment did not
substantially affect the plasma levels of sorafenib parent drug
or of its primary oxidated metabolite sorafenib-N-oxide (Fig-
ure 3d–f). This observation is consistent with our previous
finding that sorafenib itself is not a transported substrate of
Oatp1b2,9 and with the contention that the applied single
dose of rifampin is unlikely to have artificially influenced other
enzymes and transporters of relevance to the disposition of
sorafenib or SG.
Effects of rifampin on SG disposition in humans
We next assessed the influence of pretreatment with rifampin
(two daily oral doses of 600 mg) on the pharmacokinetics
(PK) of SG in human subjects receiving oral sorafenib using
an open-label randomized crossover design. All patients met
our criteria to be at steady state, as all patients were treated
at the same dose for 14 days or more at the first day of
PK sampling. As predicted from the murine pharmacoki-
netic studies, we found that concomitant rifampin adminis-
tration resulted in acute, statistically significant increases in
the systemic exposure to SG (32.5 μg × h/mL versus 14.6
μg×h/mL; P< 0.001) (Figure 4a; Supplementary Table S2),
and this was independent of the randomization sequence
(Figure 4b).
The mean metabolic ratios of SG to sorafenib in the
studied patient cohort were also significantly increased
www.cts-journal.com
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Figure 3 Pharmacokinetics of sorafenib and SG in wildtype and Oatp1b2(-/-) mice. Plasma concentration–time profiles of SG (a) and
sorafenib (d) in wildtype mice and Oatp1b2(-/-) mice in the presence and absence of rifampin pretreatment. Corresponding area under the
plasma concentration–time curves (AUC0-7.5) of SG, sorafenib, and sorafenib-N-oxide (S-N-oxide) are shown in (b), (e), and (f). Sorafenib
was administered orally at a dose of 10 mg/kg with or without pretreatment with rifampin (20 mg/kg). Livers were taken at 7.5 h after
sorafenib administration (n = 4 per group), with results expressed as the liver-to-plasma concentration ratio of SG (c). Concentrations in
liver were normalized to corresponding concentrations in plasma. All data represent the geometric mean and the 95% confidence interval.
during rifampin administration (Figure 4c). No statistically
significant differences were observed in the PK parameter
estimates of sorafenib (Figure 4d). Although the mean ratio
between 1’-hydroxymidazolam and midazolam, used as a
measure of CYP3A4 activity changes,25 was2 times higher
after rifampin intake (P = 0.005; Figure 4e), the extent of
sorafenib-N-oxide formation was not different between treat-
ment cycles (Figure 4f). During the course of the clinical
study, no toxicities were observed that could be attributed
to rifampin or midazolam. Liver function remained adequate
during the study for all patients, although one experienced
liver enzyme elevations due to cholestasis, for which previ-
ously placed biliary stents were replaced after the study. In
another patient, bilirubin levels in plasma were elevated from
14–29 μM (upper limit of normal, 16 μM) on the second day
of rifampin intake, but bilirubin levels normalized to baseline
within 2 days.
DISCUSSION
This study shows that acute inhibition of the hepatic uptake
transporter OATP1B1 by rifampin results in a PK interac-
tion with SG at steady state in human subjects receiving
oral sorafenib. This finding emphasizes the need to consider
hepatic handling of xenobiotic glucuronides in the design
of PK drug–drug interaction studies of agents that undergo
extensive phase II conjugation, and can potentially have
clinical relevance for the chemotherapeutic treatment with
sorafenib.
It was previously suggested based on in vitro microso-
mal studies that the most prominent pathway of sorafenib
elimination consists of CYP3A4-mediated metabolism lead-
ing to the formation of sorafenib-N-oxide and several other
metabolites.8 This finding suggested that sorafenib was
potentially subject to a host of CYP3A4-mediated drug inter-
actions with commonly coprescribed medications.26 Here,
the AUCs of the CYP3A4-mediated metabolites of midazo-
lam and sorafenib were increased after pretreatment with
rifampin. As the ratio of sorafenib-N-oxide to sorafenib did
not change between both cycles, the interaction of rifampin
on sorafenib-N-oxide formation does not seem to be clini-
cally relevant. In this context, it is noteworthy that the proto-
typical CYP3A4 inhibitor ketoconazole was previously found
to have no influence on the PK of sorafenib in healthy male
volunteers after single-dose sorafenib administration, sug-
gesting that the fraction of sorafenib that is metabolized by
the phase I oxidative pathway is low.12 In contrast, although
clinical data suggest that sorafenib glucuronidation accounts
for only 15% of the dose, it is likely that this percentage is
grossly underestimated,13 and may be increased further if
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Figure 4 Influence of rifampin on the pharmacokinetics of sorafenib in humans. Plasma concentration–time profiles of SG (a) and sorafenib
(d) in patients with hepatocellular carcinoma in the presence and absence of rifampin pretreatment. The corresponding area under the
plasma concentration–time curve (AUC0-7.5) of SG is shown as a function of the randomization sequence of the crossover trial (b). The
metabolic ratios for SG to sorafenib and sorafenib-N-oxide (S-N-oxide) to sorafenib are shown in (c) and (f), respectively. The metabolic
ratio for the AUC0-6 of 1′-hydroxy-midazolam (1′-OH-MDZ) to the AUC0-6 of midazolam (MDZ) is shown in (e). All data represent the
geometric mean and the 95% confidence interval and all metabolic ratios were corrected for molecular weight.
the competing CYP3A4-mediated pathway is inhibited.12 The
long-term clinical implications of such PK drug–drug interac-
tions remain unstudied.
The use of rifampin as an OATP1B1 inhibitor in our stud-
ies was based on considerations published elsewhere.20 The
relatively strong impact of rifampin on SG levels in mice
(>ninefold increase) compared with humans (2-fold) likely
reflects a differential direct influence of rifampin on the uptake
of sorafenib itself into hepatocytes, which process is par-
tially dependent on OATP1B-type transporters in humans but
appears of less relevance in mice.9 In addition, SG is known
to undergo substantial renal excretion in humans but not in
mice,13 and the possible presence of a rifampin-insensitive
escape mechanism in the kidney may result in shunting of
SG to urine when OATP1B1 function in humans is impaired.
It should also be pointed out that, although acute exposure
to rifampin inhibits OATP1B1,27 extended daily administra-
tion of rifampin may induce enzymes and transporters of
putative relevance to sorafenib. For example, exposure
to rifampin for 5 days or more dramatically increased the
clearance of the CYP3A4 substrate drugs midazolam,28
alfentanil,29 and erythromycin.30 Several recent studies have
evaluated the effects of acute and extended exposure to
rifampin on CYP3A4 activity in the same individuals. For
example, rifampin given once daily for 1–2 doses of 600
mg each (acute exposure) and the same dose administered
for 6.5 days (extended exposure) changed the systemic
exposure to bosentan, a dual OATP1B1 and CYP3A4 sub-
strate drug, by +500% and –58%, respectively.31 Thus,
if induction of enzymes occurs, it is likely that rifampin
exposure for 5 days or more is required to cause a clinically
relevant, induced CYP3A4 phenotype. Because CYP3A4
induction seems to play only a modest role in our study,
the present observations with sorafenib in conjunction with
acute exposure to rifampin may not be extrapolated to the
situation where the agent is coadministered with rifampin
for an extended period of time. Moreover, the current study
does not show whether prolonged OATP1B1 inhibition by
other drugs leads to stronger effects on the PK of sorafenib
and its metabolites than those observed here.
Interestingly, administered at a dose of 600 mg once daily
for 5 days with a single oral dose of sorafenib in healthy
volunteers, rifampin was previously found to cause a 37%
decrease in the mean systemic exposure to sorafenib.32
The causal connection of this observation with altered
CYP3A4 activity, however, remains uncertain and other
plausible mechanisms could contribute to the reported
observations. For example, prolonged exposure to rifampin
can significantly upregulate OATP1B1 and ABCC2 in pri-
mary hepatocytes.33 It can also induce UGT1A9 mRNA and
UGT1A9 activity in human subjects after 6 days of exposure
to a once-daily dose of 600 mg, although morinidazole was
only minimally affected.34 Interestingly, prolonged treat-
ment with rifampin may also affect the hepatic expression
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and function of the uptake transporter OCT1,35 which has
been proposed as a possible hepatic uptake carrier of
sorafenib.8,36 However, this may not be of concern clinically,
since recent studies in mice with a hepatic OCT1-deficiency
indicate this transporter plays only a relatively minor role in
the overall elimination of sorafenib.37 As basolateral efflux
via ABCC3 seems a prerequisite for hepatocyte hopping
(Figure 1), differential functioning of this transporter—due
to genetic polymorphisms or due to exogenous induction
or inhibition—might also play a vital role in the processes
described here. This study, however, was not designed to
take that effect into account. Also OATP1B3, functioning
identical to OATP1B1, is likely to have contributed to these
findings, especially since it is also inhibited by rifampin. How-
ever, hepatocellular expression of OATP1B3 is lower than
that of OATP1B1 and cells overexpressing the latter have
higher uptake of SG than those overexpressing the former.9
The potential clinical ramifications of the hepatocyte-
hopping phenomenon of SG and the impact of interference
in this process with transporter inhibitors such as rifampin
requires additional investigation. For example, further study
is required to determine if excessive systemic accumula-
tion of SG can lead to increases in adverse events, as has
been observed with morphine-6-glucuronide.38 This possi-
bility is consistent with the notion that certain reduced func-
tion variants in SLCO1B1, the gene encoding OATP1B1,
are associated with increased risk of sorafenib-associated
toxicity.39 Future research is also required to evaluate the
consequences of a reduced biliary excretion of SG on main-
taining plasma concentrations of sorafenib. This connection
is plausible, considering that sorafenib undergoes entero-
hepatic recirculation40 following bacterial β-glucuronidase-
mediated deconjugation of SG within the intestinal lumen,41
and would be consistent with the fact that intentional interfer-
ence of this deconjugation by neomycin is associated with a
decrease in the systemic exposure to sorafenib by more than
50% (Nexavar package insert).
Overall, our findings signify an important contribution of
OATP1B1 in the hepatocellular handling of sorafenib in
humans, whereby compromised OATP1B1 function leads
to systemic accumulation of SG through a sinusoidal liver-
blood shuttling process known as hepatocyte hopping. We
expect that the current observations with sorafenib may
have relevance to other kinase inhibitors that undergo exten-
sive phase II conjugation through glucuronidation, such
as dasatinib, regorafinib, and trametinib (Supplementary
Table S3). The PK of these drugs could also be altered
in the presence of other OATP1B1-interacting agents such
as clarithromycin42 and ramipiril.22 Establishing the clini-
cal significance of this interaction between kinase inhibitors
and agents that potently inhibit OATP1B-type transporters is
warranted.
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